Key Drivers
- Margin Expansion
- Strong Cash Flow
- Rich Valuation
AIAI Summary
LNTH has shifted from a standalone growth story to a transaction-driven trade where the Curium cash-plus-CVR deal likely caps upside, so the key investment focus is whether the transaction closes cleanly and whether strong cash flow/FDA progress can still support CVR realization or a better outcome.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Expansion
- •Strong Cash Flow
- •Rich Valuation
LNTH shows strong profitability, cash generation, and improving leverage/liquidity, but its elevated valuation and heavy intangible asset base temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Tight consolidation
- •Reclaim needed
LNTH has drifted lower over the last month, but its tight consolidation around $100.7-$101.5 near support suggests selling pressure may be easing, even though the short-term trend remains cautious until it reclaims $102.6-$104.8.
Sharp drop from $108.03 on 2026-07-27 to $99.64 on 2026-07-31 signaled sudden seller control
Sentiment & News
Key News Insights:
- •Curium takeover
- •Shareholder probes
- •FDA approval
Lantheus' period was dominated by its planned $102.50/share cash-plus-CVR sale to Curium, which sparked shareholder investigations, while Q2 results were mixed and an FDA approval added a late positive catalyst.
The pending acquisition is now the primary stock driver, with deal value supporting shares but legal and process scrutiny adding risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings